Skip to main content

Steqeyma FDA Approval History

Last updated by Judith Stewart, BPharm on Dec 19, 2024.

FDA Approved: Yes (First approved December 17, 2024)
Brand name: Steqeyma
Generic name: ustekinumab-stba
Dosage form: Injection
Company: Celltrion USA
Treatment for: Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease, Ulcerative Colitis

Steqeyma (ustekinumab-stba) is a human interleukin-12 and -23 antagonist biosimilar to Stelara used for the treatment of plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.

Development timeline for Steqeyma

DateArticle
Dec 17, 2024Approval FDA Approves Steqeyma (ustekinumab-stba), a Biosimilar to Stelara

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.